If you look at his bio on linkdin you'll see his resume highlights acquisitions. IE he gets on a board and helps them sell. I personally believe the deal to sell to $ABT is all but done, waiting on the FDA to nail down which contract they're going to sign. With the deal done there's nothing to do and he probably had a good opportunity to move on to a new company in the interim. Just speculation of course. The majority of the ST refugees on stock twits will of course disagree. YMB is certainly becoming a toxic place to post if you've got positive info -- right down to personal attacks! So you guys have definitely missed out on some of the more positive things we've found on the OTHER board :) But don't worry -- or do -- good things are coming despite yourselves :-P
Sentiment: Strong Buy
What we don't see in ABT marketing is much greater than what we do see.
Sentiment: Strong Buy
He did a dinner in Detroit. So? ABT launches a new drug and spends millions and millions. They launch Galectin-3 and have a handful of VERY BRAVE people meet in downtown Detroit - and charged them 20 bucks for the dinner. Talk about doing the bare minimum...but you and others continue to look for the pony in the pile of poo.
Another ABT venue for ABT marketing of valuable Galectin3 test.
Sentiment: Strong Buy
It means nothing. They don't need many people to run the ship as they are awaiting revenues from ABT and 2nd indication. They are continuing in their cost cutting measures.
Harris obviously knew what was happening behind the scenes. He was on the board and key committees. And he has a good background in the industry. He's not ignorant. So why leave, why leave now, why just before Q3 ends (interesting timing, so you have deniability about how the Q ends?), why leave without any good explanation from him or management as to why, and why announce on a Friday after the market, which is when many company post bad news hoping it gets lost? Hall is not talking. Sohmer is not talking. The board is not talking, so this is the only signal coming from the company and you can draw your own conclusions on what it all means.
sales, sales,sales.sales. There is no plan b or plan c. Once a clearer picture unfolds regarding sales outlook then my guess is this company will be sold asap. This company didn't belong on the Nasdaq to begin with. This is where it should have been from day one - right here. It used to be the BB market had companies mostly in the development stage and once product and sales are achieved they move to the big boards. It got all out of whack recently as plenty of garbage companies were dumped on mainstreet by wall street in another one of those (20/20 hindsight) scams - that always come crashing down once reality hits. If this product delivers what many investors hoped it would in terms of providing a valuable tool in heart failure diagnostics, then sales will save this stock and company from oblivion. This is not a one company problem but the entire markets on Wall St are nothing more than a cesspool of treacherous vipers. The management teams of about 98% of the companies are no better than the scoundrels who peddle their #$%$.
I agree its never good when you see people jumping ship. Each day it just gets worse with BG
stock. It's back to falling each day after it leveled off a bit last week. Seeing it hit the 30's again
this looks to test the lows or take it lower.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 21, 2015, Timothy Harris, Ph.D., notified BG Medicine, Inc. (the “Company”) that he was resigning from the Company’s Board of Directors (the “Board”), effective as of September 22, 2015. Dr. Harris did not communicate any disputes regarding the Company’s operations, policies or practices to the Company in connection with this resignation, nor is the Company aware of any. In connection with his departure from the Board, Dr. Harris also departs from the Board’s Audit Committee, which will continue to be comprised of Harrison M. Bains (Chair) and Stelios Papadopoulos, Ph.D.
Seen this before, people leaving for no reason smells of BK.
Sentiment: Strong Sell
I am from the BG board, made it from there and loss lots. I expect some end of year selling for taxes to continue a drop further. Ill play when its in penny land depending on revs that are supposedly incoming but glad to see you made it here. GL.
Sentiment: Strong Sell
The problem is we can't squeeze blood out of a turnip. I think they are milking the company for what they can.
For now its a paycheck. Those are my thoughts.
I am still mad about that last offering that took this down. I can see a premium but a premium near 30%
below what the PPS was at the time cut us down fast. Like one other poster called it a hatchet job...
Bigsky, you've been staring at the sun too long. Galectin-3 is for people who ALREADY have heart failure. This has nothing to do with psoriasis. BG doesn't have a patent for that. BG doesn't have a FDA approval for that. Stop cutting and pasting press releases that are totally unrelated and go back to cutting out supermarket coupons. You're going to need them, genius.
I just called Hall's Voicemail and left a very mean message. It doesn't matter. It's in some virtual voicemail hole. I just feel better.
I just called the "RECEPETIONIST", or the number that actually gave me a human being last week, and told me that she was not allowed to give out email addresses. Today, all I get is 20 rings then a busy signal.
I am all ready to start a lawsuit if we have any chance at all.
I know it was tossed around, but do we have any merit to stand on? Your thoughts needed.
Hopefully they test for Heart Failure every time they do a blood-test. Galectin 3 is a good biomarker to monitor.
New News from GALT
The genesis of this study is the apparent remission of a patient with severe psoriasis who participated in the Company's Phase 1 study cohort of 4 mg/kg of GR-MD-02 for the treatment of non-alcoholic steatohepatitis (NASH). That patient received her fourth infusion of GR-MD-02 in May 2014, and her psoriasis remained in complete remission for 17 months, with slight scaling becoming evident on her elbows just this month.
"We are excited to begin this study at the Brooke Army Medical Center in San Antonio, Texas," said Peter G. Traber, M.D., Galectin's president, chief executive officer and chief medical officer. "We know from the scientific literature that galectin-3 is at higher levels in the skin of psoriasis patients, and that GR-MD-02 inhibits galectin-3. It would follow that GR-MD-02 could affect this disease. We are hopeful that patients with moderate-to-severe plaque psoriasis will show a clearing of their disease without the negative side effects associated with many of the currently available therapies. In addition, a successful pilot study would add to our robust therapeutic pipeline for this compound."
I agree with that if such was the case for heart but testing for concussions will do nothing for
FDA approved BG auto test.
Every College and Pro Athlete should be tested for heart failure using the new Abbott test if available. Smart doctors will monitor Galectin-3 levels as a biomarker for athlete's organ health, since they are more at risk for heart failure when competing.